EP0590076A4 - Production of human hemoglobin in transgenic pigs - Google Patents

Production of human hemoglobin in transgenic pigs

Info

Publication number
EP0590076A4
EP0590076A4 EP92914572A EP92914572A EP0590076A4 EP 0590076 A4 EP0590076 A4 EP 0590076A4 EP 92914572 A EP92914572 A EP 92914572A EP 92914572 A EP92914572 A EP 92914572A EP 0590076 A4 EP0590076 A4 EP 0590076A4
Authority
EP
European Patent Office
Prior art keywords
production
human hemoglobin
transgenic pigs
pigs
transgenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP92914572A
Other languages
English (en)
French (fr)
Other versions
EP0590076A1 (en
Inventor
John S Logan
Steven Holtzman
J Kevin O'donnel
Stephen H Pilder
Carl A Pinkert
Mark E Swanson
Hillary Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DNX Corp
Original Assignee
DNX CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DNX CORP filed Critical DNX CORP
Publication of EP0590076A1 publication Critical patent/EP0590076A1/en
Publication of EP0590076A4 publication Critical patent/EP0590076A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP92914572A 1991-06-14 1992-06-15 Production of human hemoglobin in transgenic pigs Ceased EP0590076A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71777491A 1991-06-14 1991-06-14
US717774 1991-06-14
PCT/US1992/005000 WO1992022646A1 (en) 1991-06-14 1992-06-15 Production of human hemoglobin in transgenic pigs

Publications (2)

Publication Number Publication Date
EP0590076A1 EP0590076A1 (en) 1994-04-06
EP0590076A4 true EP0590076A4 (en) 1997-02-12

Family

ID=24883435

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92914572A Ceased EP0590076A4 (en) 1991-06-14 1992-06-15 Production of human hemoglobin in transgenic pigs

Country Status (5)

Country Link
EP (1) EP0590076A4 (ja)
JP (1) JPH06508035A (ja)
AU (1) AU2249592A (ja)
CA (1) CA2111348A1 (ja)
WO (1) WO1992022646A1 (ja)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872868B1 (en) 1981-06-12 2005-03-29 Ohio University Transgenic mammals
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US6204009B1 (en) 1988-05-16 2001-03-20 BAXTER BIOTECH TECHNOLOGY SàRL Nucleic acids encoding mutant recombinant hemoglobins containing heme pocket mutations
US6150506A (en) * 1989-05-10 2000-11-21 Baxter Biotech Technology Sarl Modified hemoglobin-like compounds and methods of purifying same
US5922854A (en) * 1991-06-14 1999-07-13 Kumar; Ramesh Purifying Human Hemogloblin from transgenic pig red cells and plasmids containing pig globin nucleic acids
JPH07507921A (ja) * 1992-06-12 1995-09-07 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5840851A (en) * 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5665869A (en) * 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5821351A (en) * 1994-06-10 1998-10-13 Dnx Biotherapeutics Production of hemoglobin having a delta-like globin
US6022738A (en) * 1995-03-03 2000-02-08 Mount Sinai School Of Medicine Of The City University Of New York Vectors for expression of globin genes
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US6812207B1 (en) 1995-10-23 2004-11-02 William Marsh Rice University Hemoglobin mutants that reduce heme loss
JPH11514237A (ja) * 1995-10-23 1999-12-07 ライス ユニバーシティ ヘム損失を減少させるヘモグロビン変異体
EP0863918A1 (en) * 1995-11-30 1998-09-16 Somatogen Inc. Method for control of functionality during cross-linking of hemoglobins
JP2000504934A (ja) 1995-12-22 2000-04-25 バクスター バイオテク テクノロジー エス．アー．アール．エル． 結合ドメインを含むグロビン
EP1494714A4 (en) 2002-04-05 2008-03-05 Amgen Inc HUMAN ANTI-OPGL NEUTRALIZING ANTIBODIES AS SELECTIVE OPGL PATH HEMMER
EA018072B1 (ru) 2002-09-06 2013-05-30 Амджен Инк. Антитело к рецептору интерлейкина-1 типа 1 (il-1r1) и его применение
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
NO345593B1 (no) 2005-07-18 2021-05-03 Amgen Inc Humane anti-B7RP1 nøytraliserende antistoffer
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
RS56743B1 (sr) 2007-08-21 2018-03-30 Amgen Inc Humani c-fms antigen vezujući proteini
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CA2705923A1 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
EP2606130B1 (en) 2010-08-16 2019-03-13 Duke University Camkk-beta as a marker in prostate cancer
MX354481B (es) 2010-10-27 2018-03-07 Amgen Inc Anticuerpos dkk1 y métodos de uso.
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
US20140227265A1 (en) 2011-06-17 2014-08-14 Amgen Inc. Method of treating or ameliorating metabolic disorders using clec-2
EP2788384B1 (en) 2011-12-08 2017-08-09 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
IL307989A (en) 2012-04-27 2023-12-01 Novo Nordisk As Human CD30 ligand antigen-binding proteins
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
MX2015013181A (es) 2013-03-15 2015-12-11 Amgen Inc Anticuerpos humanos pac1.
WO2014144553A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
TW201620938A (zh) 2014-09-15 2016-06-16 安美基公司 雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
EP3350216A1 (en) 2015-09-15 2018-07-25 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
JP6948330B2 (ja) 2015-12-23 2021-10-13 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対する結合タンパク質をｇｌｐ−１アゴニストと組み合わせて使用する、代謝障害の治療方法または寛解方法
US20230137351A1 (en) 2016-11-14 2023-05-04 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
US20210346513A1 (en) 2017-08-04 2021-11-11 Amgen Inc. Method of conjugation of cys-mabs
EP3737699A1 (en) 2018-01-12 2020-11-18 Amgen Inc. Pac1 antibodies and uses thereof
CN114174344A (zh) 2019-05-30 2022-03-11 美国安进公司 工程改造铰链区以驱动抗体二聚化
MX2021015791A (es) 2019-06-28 2022-04-01 Amgen Inc Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
TW202128160A (zh) 2019-10-18 2021-08-01 美國加利福尼亞大學董事會 用於治療病原性血管病症之方法及組合物
WO2021092355A1 (en) 2019-11-08 2021-05-14 Amgen Inc. Engineering charge pair mutations for pairing of hetero-igg molecules
CA3160438A1 (en) 2019-11-19 2021-05-27 Amgen Inc. Novel multispecific antibody format
EP4200338A1 (en) 2020-08-20 2023-06-28 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
WO2022076474A2 (en) 2020-10-07 2022-04-14 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
WO2022103773A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Novel linkers of multispecific antigen binding domains
AU2022263406A1 (en) 2021-04-20 2023-10-19 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009179A1 (en) * 1987-05-16 1988-12-01 Somatogenetics International, Inc. Blood substitutes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009179A1 (en) * 1987-05-16 1988-12-01 Somatogenetics International, Inc. Blood substitutes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOFFMAN, S.J. ET AL.: "Expression of fully functional tetrameric human hemoglobin in Escherichia coli", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 21, November 1990 (1990-11-01), WASHINGTON US, pages 8521 - 8525, XP002020074 *
LOOKER, D. ET AL.: "A human recombinant haemoglobin designed for use as a blood substitute", NATURE, vol. 356, no. 6366, 19 March 1992 (1992-03-19), LONDON GB, pages 258 - 260, XP002020075 *
See also references of WO9222646A1 *

Also Published As

Publication number Publication date
WO1992022646A1 (en) 1992-12-23
JPH06508035A (ja) 1994-09-14
AU2249592A (en) 1993-01-12
CA2111348A1 (en) 1992-12-23
EP0590076A1 (en) 1994-04-06

Similar Documents

Publication Publication Date Title
EP0590076A4 (en) Production of human hemoglobin in transgenic pigs
EP0713493A4 (en) PRODUCTION OF HUMAN HEMOGLOBIN IN TRANSGENIC PIGS
FI946004A (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
AU4492489A (en) Glucan dietary additives
AU2080988A (en) Esters of 13-trans-retinoic acid
EP0497204A3 (en) Medical member and method of manufacturing the same
IL115733A (en) Binding agents to cd23 and their use in the manufacture of a medicament
AU1798995A (en) Use of extracts of filamentous bacteria as cosmetic agents to combat ageing of the skin
HU9503451D0 (en) The treatment of small animals
AU5048090A (en) Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasm in human body, and the cloning of full length cdna thereof
EP0655888A4 (en) PRODUCTION OF HUMAN HEMOGLOBIN IN TRANSGENIC PIGS.
FI950909A (fi) Rasvahappojohdannaisia
DK0610286T3 (da) Rekombinante immunotoxiner
IL138290A0 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
FI931204A0 (fi) Nya, saosom lipooxigenasinhibitorer verkande aminobensosultamderivat
ATE126058T1 (de) Dermatologische zusammensetzungen mit einem gehalt an cis-urocaninsäure.
ES2058451T3 (es) Un metodo para la preparacion de una composicion farmaceutica.
MD980129A (en) Antiherpetic remedy
AU7780791A (en) Neonatal human blood bank and hematopoietic or immune reconstitutions performed therewith
WO2001017536A3 (de) Neue autovakzinen zur erzielung einer immuntoleranz
EP0407788A3 (en) Use of retinoids for the treatment and prophylaxis of immune related diseases
GB2257155B (en) Treatment of animal horn by the application of heat and pressure
NO944811L (no) Produksjon av humant hemoglobin i transgene griser
MY101875A (en) Lankacidin derivatives and production thereof.
Todd The field of the psyche and the cultivation of human nature

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: C12N 15/12

A4 Supplementary search report drawn up and despatched

Effective date: 19961223

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19980717

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20011004